Novo Nordisk offers Ozempic Wegovy sold 199 per month for new self-paying patients from Nov. 17 to March 31 with discounted initial doses.

Novo revealed Monday that the self-pay cost for the two lowest dosages of Wegovy and Ozempic will be $349 per month, down from $499, which itself was a markdown earlier this year from Wegovy’s previous cash-pay price of $650. The highest doses of both meds will still run for $499.

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

The drugs have become popular for their significant weight-loss effects, but their high cost has made them inaccessible for many patients.

Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.

New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as the Federal Trade Commission intervened to raise concerns about the potential merger.

Generic drugmaker Sandoz expects unbranded versions of Novo Nordisk's blockbuster diabetes drug Ozempic to launch in Canada by the end of June next year after a key patent expires, its CEO told Reuters on Wednesday.